H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

Researchers from Moffitt Cancer Center and partners analyzed genomic data from over 5,000 veterans with metastatic prostate cancer, finding significant biological differences between non-Hispanic Black and white patients.

RyboDyn has expanded its strategic partnership with Moffitt Cancer Center to accelerate development of immunotherapies targeting novel cancer-specific proteins identified through its proprietary RyboCypher™ platform.

Anitocabtagene autoleucel (anito-cel) utilizes a novel D-Domain binder for BCMA targeting, offering potentially higher transduction efficiency and CAR density compared to traditional CAR T therapies.

Moffitt Cancer Center researchers discovered that blocking nitrosylation makes aggressive NRAS-mutant melanoma more responsive to treatment, enhancing both drug efficacy and immune response against the cancer.

• A new study published in PLOS Medicine demonstrates that self-administered HPV tests accurately identify women with cervical cancer or precancerous cells, with 40% of high-risk group participants requiring treatment. • The U.S. Preventive Services Task Force recently endorsed self-collection for HPV testing as an option for women over 30, following FDA approval of a self-testing kit in May 2024. • Researchers stratified HPV-positive women into risk groups, finding that high-risk patients should proceed directly to colposcopy, while low-risk individuals (over half of positive cases) can safely wait 12 months for retesting.

A phase 3 clinical trial led by Moffitt Cancer Center demonstrates that the melphalan hepatic delivery system significantly improves progression-free survival in patients with metastatic uveal melanoma to 9.1 months versus 3.3 months with standard care.

NIH scientists have demonstrated a promising approach using patients' own immune cells to fight gastrointestinal cancers, with tumor shrinkage observed in about 25% of trial participants.

Cleveland Clinic and Moffitt Cancer Center researchers analyzed data from nearly 19,000 metastatic colorectal cancer patients, confirming immune checkpoint inhibitors significantly improve survival in MSI-H tumors compared to chemotherapy alone.

Anixa Biosciences will present Phase 1 clinical trial data on its innovative ovarian cancer CAR-T therapy at the 2025 ASCO Annual Meeting in Chicago, featuring a unique chimeric endocrine receptor-T cell technology.

VCU Massey researchers discovered that combining FDA-approved sotorasib with experimental FGTI-2734 effectively overcomes resistance in KRAS G12C-mutated non-small cell lung cancer, potentially offering new hope for the 14% of patients with this mutation.